| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 165 | / | 2018 | ||||||||
| Date of issue: | 2018-12-17 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Notification for acquisition of own shares | |||||||||||
| Official market - legal basis | |||||||||||
| art. 56. 1. 2 of Act on Public Offering. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Sopharma AD (3JR: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that on December 14, 2018 the Company bought 5 000 own shares representing 0.0037% of the share capital of the Company, at a total value of 18 000.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.60 BGN. The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018. The total number of treasury shares after this transaction is 8 863 836, representing 6.58% of the share capital of the Company. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| Current report 165 buy back 14122018 espi.pdf | Notification for acquisition of own shares | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2018-12-17 | Ognian Donev | Executive director | |||
Current report 165 buy back 14122018 espi.pdf
